{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:03:14Z","timestamp":1792468994271,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Government of Japan Ministry of Education Culture Sports Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.leukres.2025.107738","type":"journal-article","created":{"date-parts":[[2025,6,23]],"date-time":"2025-06-23T11:51:56Z","timestamp":1750679516000},"page":"107738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells"],"prefix":"10.1016","volume":"156","author":[{"given":"Fumi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ieharu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinuko","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2025.107738_bib1","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107738_bib2","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/j.1460-2075.1994.tb06288.x","article-title":"Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia","volume":"13","author":"Mitani","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.leukres.2025.107738_bib3","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1111\/j.1349-7006.2008.00956.x","article-title":"Role of the RUNX1-EVI1 fusion gene in leukemogenesis","volume":"99","author":"Maki","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2025.107738_bib4","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1182\/blood-2004-11-4330","article-title":"Dysplastic definitive hematopoiesis in AML1\/EVI1 knock-in embryos","volume":"106","author":"Maki","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107738_bib5","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/sj.leu.2404281","article-title":"Development of megakaryoblastic leukaemia in Runx1-Evi1 knock-in chimaeric mouse","volume":"20","author":"Maki","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107738_bib6","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1349-7006.2007.00699.x","article-title":"Histone deacetylase inhibitors trichostatin A and valproic acid circumvent apoptosis in human leukemic cells expressing the RUNX1 chimera","volume":"99","author":"Sasaki","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.leukres.2025.107738_bib7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12185-012-1232-5","article-title":"Fadd and Skp2 are possible downstream targets of RUNX1-EVI1","volume":"97","author":"Maki","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.leukres.2025.107738_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.leukres.2018.09.015","article-title":"RUNX1-EVI1 induces dysplastic hematopoiesis and acute leukemia of the megakaryocytic lineage in mice","volume":"74","author":"Nakamura","year":"2018","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2025.107738_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2004.07.004","article-title":"Tie2\/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche","volume":"118","author":"Arai","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2025.107738_bib10","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.leukres.2025.107738_bib11","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/leu.2012.39","article-title":"Valproic acid induces differentiation and transient tumor regression, but spares leukemia-initiating activity in mouse models of APL","volume":"26","author":"Leiva","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2025.107738_bib12","article-title":"Quercetin enhances the antitumor activity of trichostatin A through upregulation of p53 protein expression in vitro and in vivo","volume":"8","author":"Chan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2025.107738_bib13","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s00432-019-02931-1","article-title":"Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia","volume":"145","author":"Forthun","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107738_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.leukres.2025.107738_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jvsv.2017.05.001","article-title":"Review of the endothelial pathogenic mechanism of TIE2-related venous malformation","volume":"5","author":"Du","year":"2017","journal-title":"J. Vasc. Surg. Venous Lymphat Disord."},{"key":"10.1016\/j.leukres.2025.107738_bib16","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nrc2894","article-title":"Targeting the ANGPT-TIE2 pathway in malignancy","volume":"10","author":"Huang","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2025.107738_bib17","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.3324\/haematol.2019.241885","article-title":"RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks","volume":"106","author":"Kellaway","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107738_bib18","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1634\/stemcells.2006-0700","article-title":"Expression of Tie-2 and other receptors for endothelial growth factors in acute myeloid leukemias is associated with monocytic features of leukemic blasts","volume":"25","author":"Riccioni","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.leukres.2025.107738_bib19","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.exphem.2008.11.007","article-title":"Increase of hematopoietic progenitor and suppression of endothelial gene expression by Runx1 expression during in vitro ES differentiation","volume":"37","author":"Sakai","year":"2009","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.leukres.2025.107738_bib20","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/s41467-023-38002-w","article-title":"Epigenetic landscape reveals MECOM as an endothelial lineage regulator","volume":"14","author":"Lv","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2025.107738_bib21","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood.2022016592","article-title":"EVI1 drives leukemogenesis through aberrant ERG activation","volume":"141","author":"Schmoellerl","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2025.107738_bib22","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/bloodadvances.2022008018","article-title":"EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment","volume":"7","author":"Masamoto","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2025.107738_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.vph.2016.05.003","article-title":"Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERG","volume":"86","author":"Shah","year":"2016","journal-title":"Vasc. Pharm."},{"key":"10.1016\/j.leukres.2025.107738_bib24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1200\/JCO.2005.05.058","article-title":"Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival","volume":"23","author":"Loges","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2025.107738_bib25","first-page":"1203","article-title":"Expression of angiopoietins and their receptor Tie2 in the bone marrow of patients with acute myeloid leukemia","volume":"91","author":"Schliemann","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2025.107738_bib26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.leukres.2007.08.010","article-title":"Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia","volume":"32","author":"Hou","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2025.107738_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00277-009-0869-5","article-title":"Shedding of the endothelial receptor tyrosine kinase Tie2 correlates with leukemic blast burden and outcome after allogeneic hematopoietic stem cell transplantation for AML","volume":"89","author":"Koenecke","year":"2010","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.leukres.2025.107738_bib28","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.leukres.2025.107738_bib29","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/cancers11111794","article-title":"HDAC inhibitors in acute myeloid leukemia","volume":"11","author":"San Jos\u00e9-En\u00e9riz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.leukres.2025.107738_bib30","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1182\/blood-2007-03-078576","article-title":"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome","volume":"110","author":"Soriano","year":"2007","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212625000980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T13:55:52Z","timestamp":1756821352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212625000980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S0145212625000980"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107738","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC inhibitors repress Tek and Angpt1 expression and proliferation in RUNX1-MECOM-type leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2025.107738","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107738"}}